Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain
Table 3
Secondary hormonal treatment approaches ().
Value
Antiandrogen withdrawal; (%)
99 (56.9)
LHRH agonists; (%)
59 (33.9)
Continue the patient on initial LHRH agonist
51 (86.4)
Switch to a different LHRH agonist
8 (13.6)
Addition of antiandrogens; (%)
47 (27.0)
Nonsteroidal antiandrogens
41 (87.2)
Steroidal antiandrogens
6 (12.8)
Adrenal testosterone inhibitors; (%)
26 (14.9)
Ketoconazole
21 (84.0)
Corticoids
4 (16.0)
Continue the patient on initial treatment; (%)
25 (14.4)
Antiandrogen replacement; (%)
12 (6.9)
Nonsteroids
8 (66.7)
Steroids
4 (33.3)
Estrogenic compounds
8 (4.6)
Data are expressed as (percentage of total second hormonal manipulation and option used). Percentages may add up more than 100% as patients could receive more than one hormonal manipulation. LHRH: luteinising hormone-releasing hormone. One missing data.